Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Consult your doctor before starting supplementation.
Receptor-target and efficacy comparison: GLP-1 class agents | Agent | GLP-1 | GIP | Glucagon | Approval | Best trial weight loss | |---|---|---|---|---|---| | Liraglutide (Saxenda) | Yes | No | No | FDA-approved | 8.0% at 56 weeks (SCALE) | | Dulaglutide (Trulicity) | Yes | No | No | T2D only | 3.0 kg mean at 52 weeks | | Semaglutide (Wegovy) | Yes | No | No | FDA-approved | 14.9% at 68 weeks (STEP-1) | | Tirzepatide (Zepbound) | Yes | Yes | No | FDA-approved | 20.9% at 72 weeks (SURMOUNT-1) | | Retatrutide | Yes | Yes | Yes | Investigational | 24.2% at 48 weeks (Phase 2) | Liraglutide and Dulaglutide: Where They Fit Now Liraglutide (Saxenda, 3 mg once daily subcutaneous) was the first GLP-1 agonist approved specifically for obesity in the United States
Semaglutide helps override some of these signals, but it can't eliminate the underlying metabolic response entirely
Y.YoonH
Prioritize protein, stay hydrated, include fiber-rich foods, walk daily, get consistent sleep, and avoid grazing
Proc Natl Acad Sci United States America (2015) 112(22):70616
US$ 20.16
US$ 25.31
US$ 25.03
US$ 26.74
US$ 26.10
